GTCR Acquires Zentiva from Advent in $4.8bn Deal
Global private equity firm Advent International has agreed to sell Czech generics leader Zentiva to Chicago-based private equity firm GTCR for €4.1bn, marking one of Europe’s largest healthcare transactions of 2025 and underscoring robust investor appetite for stable pharmaceutical assets. Advent acquired Zentiva from Sanofi in 2018 for €1.9bn and exits at more than double the valuation, reflecting seven years of operational transformation. Under Advent, Zentiva doubled…